SCHEMBL12190909

SCHEMBL12190909

CC(NC(=O)c1cncc(-c2ccc(O)cc2)c1)c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 5/20 0.54
▸ SCN10A Q9Y5Y9 1/20 0.54
▸ ROCK2 O75116 9/20 0.52
▸ ROCK1 Q13464 8/20 0.52
▸ NPC1 O15118 1/20 0.50
▸ PDE2A O00408 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ RPS6KA5 O75582 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ CDK1 P06493 1/20 0.46
▸ CSF1R P07333 1/20 0.46
▸ PRKACA P17612 1/20 0.46
▸ FLT1 P17948 1/20 0.46
▸ RPS6KB1 P23443 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ AKT1 P31749 1/20 0.46
▸ FLT4 P35916 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12191092 0.89 NPC1 (0.65) XDHSCN10AROCK2ROCK1NPC1
SCHEMBL12191054 0.89 NPC1 (0.65) XDHSCN10AROCK2ROCK1NPC1
SCHEMBL12190887 0.88 ROCK2 (0.61) XDHROCK2ROCK1NPC1KMT2A
SCHEMBL12191128 0.85 GPR55 (0.53) XDHSCN10AROCK2ROCK1NPC1
SCHEMBL12190898 0.82 XDH (0.77) XDHSCN10AROCK2ALDH1A1
SCHEMBL13229283 0.81 NPC1 (0.59) XDHROCK2ROCK1NPC1KMT2A
SCHEMBL13325935 0.81 NPC1 (0.59) XDHROCK2ROCK1NPC1KMT2A
SCHEMBL13494840 0.80 NPC1 (0.74) ROCK2ROCK1NPC1KMT2AALDH1A1
SCHEMBL12191073 0.80 ROCK1 (0.67) ROCK2ROCK1RPS6KA5MAP4K4CDK1
SCHEMBL12191024 0.80 HPGDS (0.49) ROCK2ROCK1NPC1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 — — US disclosed
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 — — US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 — — US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060619-A1 Nicotinamide-based kinase inhibitors NADK, NAMPT, PDXK XDH 278/4885SCN10A 1066/4885ROCK2 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback